Fiasp® by Novo Nordisk approved in Europe

News Hour:

Novo Nordisk announced that the European Commission has granted marketing authorisation for Fiasp® for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states.

Fiasp® is the brand name for fast-acting insulin aspart. Fiasp® provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid®.

“Fiasp® is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp® are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Fiasp® will be available in vial, Penfill® and FlexTouch® pen. Novo Nordisk expects to launch Fiasp® in the first European countries in the first half of 2017.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
Yageo Corp to acquire Kemet Corp in a $1.8 billion deal
Anurag Kashyap shoots Kubra Saith 7 times nude and made her cry for frontal nudity scene [Video]
A ransomware attack hit computer servers and halted administrative work at Pemex
Paperfly launches delivery services covering 64 districts in Bangladesh
Grameenphone brings in the iPhone 11 series in Bangladesh

Advertisement

News of the Month

January 2017
S M T W T F S
« Dec   Feb »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: